Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.

[1]  Qianhui Xu,et al.  Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer. , 2022, Recent patents on anti-cancer drug discovery.

[2]  Q. Pang,et al.  NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma , 2021, BMC Cancer.

[3]  Ye Zhang,et al.  NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells , 2021, Cells.

[4]  S. Yeung,et al.  Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS , 2021, Signal Transduction and Targeted Therapy.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  Yongzhong Hou,et al.  PD-L1 degradation pathway and immunotherapy for cancer , 2020, Cell Death & Disease.

[7]  M. Wang,et al.  S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer , 2020, Oncogene.

[8]  Kristen Fousek,et al.  Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. , 2020, Pharmacology & therapeutics.

[9]  B. Thienpont,et al.  Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook , 2020, Molecular cancer.

[10]  Yi-Ching Wang,et al.  Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression , 2020, Theranostics.

[11]  J. Cheong,et al.  FoxM1-dependent and fatty acid oxidation-mediated ROS modulation is a cell-intrinsic drug resistance mechanism in cancer stem-like cells , 2020, Redox biology.

[12]  E. King,et al.  NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors , 2020, Cancer Research.

[13]  Ke Li,et al.  EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression , 2019, Molecular Cancer.

[14]  M. Hung,et al.  Mechanisms Controlling PD-L1 Expression in Cancer. , 2019, Molecular cell.

[15]  D. Raucher.  Tumor targeting peptides: novel therapeutic strategies in glioblastoma. , 2019, Current opinion in pharmacology.

[16]  K. Nakagawa,et al.  Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. , 2019, Japanese journal of clinical oncology.

[17]  Xiawei Wei,et al.  Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[18]  Qingdong Guo,et al.  Oxidative stress-elicited YY1 potentiates antioxidative response via enhancement of NRF2-driven transcriptional activity: A potential neuronal defensive mechanism against ischemia/reperfusion cerebral injury. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  D. Gomez,et al.  Proton Therapy in Non-small Cell Lung Cancer , 2018, Current Treatment Options in Oncology.

[20]  Y. Assaraf,et al.  Modulating ROS to overcome multidrug resistance in cancer. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  Feng Wang,et al.  NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR , 2018, Cell Death & Disease.

[22]  D. Toncheva,et al.  Detecting EGFR Mutations in Patients with Non-small Cell Lung Cancer , 2018, Balkan journal of medical genetics : BJMG.

[23]  Z. Ge,et al.  NOX4-driven ROS formation regulates proliferation and apoptosis of gastric cancer cells through the GLI1 pathway. , 2018, Cellular signalling.

[24]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[25]  K. Schalper,et al.  Interleukin-8 in cancer pathogenesis, treatment and follow-up. , 2017, Cancer treatment reviews.

[26]  D. Zhong,et al.  Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial‐mesenchymal transition in a lung adenocarcinoma patient with EGFR‐TKI drug resistance , 2017, Thoracic cancer.

[27]  E. King,et al.  Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4 , 2017, Journal of the National Cancer Institute.

[28]  Yan-juan Zhu,et al.  Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC. , 2017, Oncology letters.

[29]  S. Formenti,et al.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.

[30]  W. Linden,et al.  Anxiety After Diagnosis Predicts Lung Cancer-Specific and Overall Survival in Patients With Stage III Non-Small Cell Lung Cancer: A Population-Based Cohort Study. , 2017, Journal of pain and symptom management.

[31]  R. Ciampi,et al.  Targeted Therapy in Thyroid Cancer: State of the Art. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[32]  Qipeng Wu,et al.  Nrf2 mediates redox adaptation in NOX4‐overexpressed non‐small cell lung cancer cells , 2017, Experimental cell research.

[33]  Z. Guo,et al.  [Effects of high-intensity focused ultrasound on apoptosis-associated gene expression in xenografts with human pancreatic cancer]. , 2017, Zhonghua yi xue za zhi.

[34]  J. Roh,et al.  Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis , 2016, Redox biology.

[35]  Juan Li,et al.  NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells. , 2016, Free radical biology & medicine.

[36]  A. Berns,et al.  Drugging the addict: non‐oncogene addiction as a target for cancer therapy , 2016, EMBO reports.

[37]  K. Steele,et al.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.

[38]  Yong Li,et al.  Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter , 2015, Oncotarget.

[39]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[40]  K. Reckamp.  Combination chemotherapy for older adults with advanced non-small-cell lung cancer , 2011, The Lancet.

[41]  Qing Xu,et al.  MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis , 2011, Nucleic acids research.

[42]  Hyae-Young Kim,et al.  First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[44]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[45]  B. Wilson,et al.  Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase , 2009, Prostate Cancer and Prostatic Diseases.

[46]  I. Fabregat,et al.  Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. , 2008, Journal of hepatology.

[47]  Y. Rojanasakul,et al.  Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. , 2007, Cancer research.

[48]  S. Furuta,et al.  Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells , 2006, Oncogene.

[49]  Lieping Chen,et al.  Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274) , 2006, FEBS letters.

[50]  J. W. Park,et al.  Impaired generation of reactive oxygen species in leprechaunism through downregulation of Nox4. , 2005, Diabetes.

[51]  J. Lambeth.  NOX enzymes and the biology of reactive oxygen , 2004, Nature Reviews Immunology.

[52]  P. Várnai,et al.  Identification of renox, an NAD(P)H oxidase in kidney. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Yong Li,et al.  Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing. , 2016, American journal of translational research.

[54]  R. Byers,et al.  Yin Yang 1 in human cancer. , 2011, Critical reviews in oncogenesis.